INTRODUCTION
============

We will briefly review Hirschsprung disease (HSCR), multiple endocrine neoplasia type 2 (MEN2), and the co-segregation of these conditions in the few families that have been studied to date. In addition, we will discuss the existing hypotheses to explain the finding of HSCR associated with MEN2.

HIRSCHSPRUNG DISEASE
====================

HSCR (MIM \#142623) is a congenital intestinal malformation characterized by aganglionic megacolon in a variable length of the intestine; both short- and long-segment forms of the disease exist ([@b1-cln_67p57]). The incidence of this congenital megacolon is 1 per 5,000 newborns, although it varies from 1.5 in Caucasians to 2.8 in Asians for each 10,000 newborns. HSCR is a neurocristopathy most frequently found in its sporadic form (S-HSCR, ∼70% of cases) which is a non-Mendelian disease with low, sex-dependent penetrance and variable clinical expression ([@b1-cln_67p57])--([@b3-cln_67p57]). Familial forms of HSCR (F-HSCR) usually occur in association with several inherited syndromes, such as MEN2 ([@b4-cln_67p57])--([@b13-cln_67p57]). Recently, a Hirschsprung disease consortium verified that germline mutations in the *RET* proto-oncogene have been reported in up to 50% of patients with F-HSCR and in 15-20% of patients with S-HSCR ([@b2-cln_67p57]). *RET* is the major susceptibility gene for HSCR, although up to 10 genes and five different loci have been associated with HSCR development ([@b1-cln_67p57]),([@b2-cln_67p57]). The short-segment form of the condition is more frequent (80%) than the long-segment form \[20%\], and recently developed surgical approaches for both forms have a high chance of success, markedly decreasing the mortality and morbidity rates of this condition ([@b2-cln_67p57]),.

Diagnosis of HSCR is usually confirmed by rectal biopsy in newborns with intestinal obstructions with the following findings: failure of meconium delivery in the first 2 days of life, abdominal distention that is alleviated with rectal stimulus and enema, vomiting, and neonatal enterocolitis. The shorter the aganglionic segment, the later the signals and symptoms develop and consequently the more delayed the diagnosis of HSCR ([@b2-cln_67p57]),([@b3-cln_67p57]),([@b16-cln_67p57]).

MEN2
====

MEN2 (MIM \#171400) is an inherited syndrome caused by germline mutations in the *RET* proto-oncogene, which encodes the RET receptor tyrosine kinase. Three neuroendocrine neoplasias are usually present: medullary thyroid carcinoma (MTC), pheochromocytoma (PHEO), and primary hyperparathyroidism. Two other subtypes of MEN2 are familial MTC (FMTC; MTC only) and MEN2B (MTC; PHEO, and ganglioneuromas) ([@b7-cln_67p57]),([@b13-cln_67p57]),([@b18-cln_67p57]),([@b19-cln_67p57]).

HIRSCHSPRUNG DISEASE CO-OCCURRING WITH MEN2
===========================================

In MEN2A, MTC and PHEO are the most prevalent causes of morbidity and mortality, although HSCR is also an infrequent but potentially life-threatening MEN2 phenotype ([@b2-cln_67p57]),([@b18-cln_67p57]),([@b19-cln_67p57]). In contrast, in sporadic MTC there are no other associated neuroendocrine tumors and HSCR has not been reported to date ([@b20-cln_67p57]),([@b21-cln_67p57]).

Recently, an international consortium on RET exon 10 studied 340 affected subjects from 103 MEN2 families and assessed the risk profiles and penetrance estimations of MEN2 patients who were diagnosed with germline *RET* mutations in exon 10. In this study, 267 MEN2 patients were investigated for HSCR disease and an overall penetrance of 7.5% was observed ([@b22-cln_67p57]). Of note, carriers of germline *RET* mutations in codon 620 were more prone to HSCR (13%), especially those with C620R or C620G substitutions (14--33%), although *RET* 618 and 609 codon mutation carriers may also present with HSCR ([@b22-cln_67p57]).

Present hypotheses
------------------

The co-occurrence of the HSCR and MEN2 (HSCR/MEN2) phenotypes raises an apparent paradox because MTC is caused by activation of cellular growth signaling of the RET tyrosine kinase receptor, while HSCR is largely associated with disruption of this pathway because of inactivating *RET* mutations ([@b1-cln_67p57]). Initially it was thought that disturbed mechanisms of apoptosis might lead to HSCR ([@b23-cln_67p57]). Several investigations have examined this topic ([@b24-cln_67p57])--([@b33-cln_67p57]).

At present, there are two main hypotheses to explain the occurrence of HSCR/MTC within MEN2 families. The first states that MEN2-associated *RET* mutations, mostly in exon 10, may play a dual activating and inactivating role in the RET tyrosine kinase molecular pathway, leading to constitutive activation of the RET receptor. The mutated RET receptor would present a tissue-specific tendency to be retained in the Golgi apparatus, leading to a reduced number of RET membrane receptors in the intestine and, therefore, decreased intracellular tyrosine signaling ([@b24-cln_67p57]).

The second hypothesis is that the *RET*-activating mutations play either no role, or only a minor role, in HSCR development ([@b2-cln_67p57]). In this scenario, low-penetrant and dose-dependent, specific predisposition to *RET* haplotypes may lead to a reduction in RET tyrosine receptor activation during embryonic life, leading to neuronal and intestinal cell disturbances and, finally, HSCR. Of note, both protective and predisposing haplotypes to HSCR have been described ([@b2-cln_67p57]). There is strong evidence favoring the hypothesis that specific haplotypes play a key role in the fetal development of congenital megacolon ([@b2-cln_67p57]),([@b32-cln_67p57]). Recent data suggest that mutations in *RET* ligand genes may be responsible for a small proportion of HSCR cases ([@b33-cln_67p57]).

As previously mentioned, the prevalence of HSCR in MEN2 cases has been recently determined to be 7.5% ([@b22-cln_67p57]). Borrego et al. ([@b10-cln_67p57]) reported that 13 HSCR/MEN2 families had been described up to 1998. At present, up to 22 HSCR/MEN2 families have been reported, although the number of families that have been genetically investigated is relatively limited ([@b2-cln_67p57]),([@b4-cln_67p57]),([@b12-cln_67p57]). S-HSCR or F-HSCR cases have been extensively studied clinically; however, further genetic haplotype analyses may contribute to a better understanding of the molecular causes of familial HSCR associated with MEN2.

LOCAL EXPERIENCE
================

Although a limited number of affected familial cases from this new FMTC/MEN2 genealogy could be studied, data from patients with either MTC alone or HSCR associated with MTC/MEN2 were available to be analyzed.

A novel HSCR/FMTC family
------------------------

Herein we report the results of the genotyping analysis of a novel HSCR/FMTC family that carries the germline c.1858T\>C (p.C620R) *RET* activating mutation in exon 10. The patients come from a rural area of northeast Brazil and have been diagnosed, treated and followed for several years at the University of São Paulo School of Medicine, Academic Hospital (Hospital das Clínicas, southeast Brazil) ([Figure 1](#f1-cln_67p57){ref-type="fig"}). Early recognition of HSCR in the studied cases was achieved with routine investigations for HSCR ([@b15-cln_67p57]),([@b16-cln_67p57]). The recommended surgical approach for HSCR was used, allowing the affected patients in the study to survive longer ([@b14-cln_67p57]),([@b17-cln_67p57]). The two patients with HSCR/MEN2 who were operated on in our hospital had the long-segment form of HSCR. No renal/urinary disturbances were observed in our cases, consistent with the findings from the HSCR mouse model ([@b34-cln_67p57]). Several *RET* gene mutation carriers from this family underwent preventive or curative total thyroidectomy. We have recently reported partial phenotypic data obtained from this large FMTC/MEN2 family ([@b22-cln_67p57]).

Visit to the area
-----------------

During a recent visit to the area where the family originally lived and where most patients still live (2,500 km from São Paulo), written informed consent was obtained and blood samples for DNA analysis were collected from several at-risk family members. The researchers were informed that the family had experienced three neonatal deaths of babies who were operated on for congenital megacolon at a local hospital, but not in time to save their lives. The institutional ethics committee has approved this research project.

Haplotype investigation
-----------------------

To verify if an additional and inactivating *RET* mutation was present in the C620R-mutated HSCR patients in this family, the 21 exons of the *RET* proto-oncogene were analyzed by polymerase chain reaction amplification and bidirectional sequencing, as previously reported ([@b35-cln_67p57]). No germline *RET* mutation other than C620R was observed. We also investigated whether *RET* single nucleotide polymorphisms (SNPs) or specific haplotypes were involved. Haplotypes were estimated using the EHPlus and Hapi software programs (<http://linkage.rockefeller.edu>). Genotyping data on 16 *RET* intragenic SNPs were as follows: rs2505533, novel SNP-1, rs2505532, rs72781232, rs2505531, rs2565206, rs1800858, rs1864404, novel SNP-2, rs1800860, rs3026750, rs34827976, rs1799939, rs1800861, rs1800862, and rs1800863 ([Table 1](#t1-cln_67p57){ref-type="table"}).

Initially, the haplotype CTCGTGGTGAdel (rs2505533, IVS1-126, rs2505532, rs72781232, rs2505531, rs2565206, rs1800858, rs1864404, rs1800860, rs3026750 and rs34827976) was documented in all of the studied C620R-mutated relatives in the present family, indicating that this haplotype is linked to the *RET* mutation.

Because not all of family members with the *RET* mutation had developed HSCR, the emerging hypothesis was that HSCR disease maybe associated with genetic variants in the remaining chromosome region. In accordance with this assumption, the MEN2-affected relatives who did not have HSCR were believed to have inherited the CATACTGTAAdel haplotype, while the HSCR/MEN2 patients had inherited a different haplotype, TTCGTTAAAGC ([Figure 1](#f1-cln_67p57){ref-type="fig"}).

The *RET* gene region that includes the observed haplotypes in this new MEN2 family, especially the combination of the SNPs from rs2505533 to rs2565206 in linkage disequilibrium with SNPs rs1800858 and rs1800861, has been previously implicated in the development of both sporadic and familial forms of HSCR ([@b1-cln_67p57]),([@b2-cln_67p57]). Furthermore, analysis of four additional members of this family with the C620R mutation (three cases without and one with HSCR) strengthened the proposal that this *RET* gene region is involved in the development of HSCR (n = 9; *p* = 0.012; Fisher exact test). It is worth noting that only HSCR patients were homozygous for the four SNPs located in the implicated region: rs2565206, rs2505532, rs72781232, and rs2505531 ([Figure 1](#f1-cln_67p57){ref-type="fig"}). Concordantly, *RET* exon 2 A45A SNP has been found in the homozygous state in cases with HSCR only, whereas MEN2 patients and healthy controls are frequently heterozygous for this SNP ([@b2-cln_67p57]),([@b31-cln_67p57]).

In summary, we have presented new evidence supporting the role of a *RET* haplotype, which is not linked to the C620R mutation, in the development of HSCR in a newly reported FMTC/MEN2 family. Our findings support the hypothesis that the occurrence of HSCR in MEN2 families is not caused by any additional *RET-*inactivating mutation. Rather, it is most likely due to the combination of low-penetrance *RET* SNPs in the previously recognized HSCR-risk region between SNPs 2505533 and 2565206. The TTCGTTAAAGC *RET* haplotype may be helpful as a genetic marker for HSCR, which would ultimately translate into improved medical care for these patients.
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###### 

Sixteen *RET* intragenic SNPs that were genotyped in patients with MTC alone or HSCR/MTC from a newly reported FMTC/MEN2 family.

  SNP[\*](#tfn1-cln_67p57){ref-type="table-fn"})   Location   DNA             Protein
  ------------------------------------------------ ---------- --------------- ---------
  rs2505533                                        Intron 1   c.74-1454T\>C   /
  Novel SNP                                                   c.74-1379T\>A   /
  rs2505532                                                   c.74-1362C\>T   /
  rs72781232                                                  c.74-1329G\>A   /
  rs2505531                                                   c.74-1290T\>C   /
  rs2565206                                                   c.74-126G\>T    /
  rs1800858                                        Exon 2     c.135G\>A       p.A45A
  rs1864404                                        Intron 5   c.1064-89A\>T   /
  Novel SNP                                        Intron 7   c.1522+58C\>A   /
  rs1800860                                        Exon 7     c.1296A\>G      p.A432A
  rs3026750                                        Intron 8   c.1648+84G\>A   /
  rs34827976                                                  c.1648+88delC   /
  rs1799939                                        Exon 11    c.2071G\>A      p.G691S
  rs1800861                                        Exon 13    c.2307T\>A      p.L769L
  rs1800862                                        Exon 14    c.2508C\>T      p.S836S
  rs1800863                                        Exon 15    c.2712C\>G      p.S904S

Please see <http://www.ncbi.nlm.nih.gov/snp>.
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